nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Conjugated Estrogens—osteoporosis	0.0899	0.328	CbGbCtD
Afatinib—ABCG2—Estradiol—osteoporosis	0.0789	0.288	CbGbCtD
Afatinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0442	0.161	CbGbCtD
Afatinib—ABCB1—Conjugated Estrogens—osteoporosis	0.0324	0.118	CbGbCtD
Afatinib—ABCB1—Estradiol—osteoporosis	0.0285	0.104	CbGbCtD
Afatinib—ERBB2—Exemestane—Estropipate—osteoporosis	0.00411	0.444	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Conjugated Estrogens—osteoporosis	0.00311	0.336	CbGdCrCtD
Afatinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.00125	0.135	CbGdCrCtD
Afatinib—Nervous system disorder—Raloxifene—osteoporosis	0.000821	0.00221	CcSEcCtD
Afatinib—Connective tissue disorder—Zoledronate—osteoporosis	0.00082	0.00221	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Estradiol—osteoporosis	0.00082	0.00221	CcSEcCtD
Afatinib—Urethral disorder—Zoledronate—osteoporosis	0.000818	0.0022	CcSEcCtD
Afatinib—Skin disorder—Raloxifene—osteoporosis	0.000813	0.00219	CcSEcCtD
Afatinib—Nervous system disorder—Ibandronate—osteoporosis	0.000813	0.00219	CcSEcCtD
Afatinib—Back pain—Risedronate—osteoporosis	0.000809	0.00218	CcSEcCtD
Afatinib—Alopecia—Pamidronate—osteoporosis	0.000808	0.00217	CcSEcCtD
Afatinib—Skin disorder—Ibandronate—osteoporosis	0.000805	0.00217	CcSEcCtD
Afatinib—Muscle spasms—Risedronate—osteoporosis	0.000805	0.00217	CcSEcCtD
Afatinib—Nausea—Ergocalciferol—osteoporosis	0.000798	0.00215	CcSEcCtD
Afatinib—Malnutrition—Pamidronate—osteoporosis	0.000796	0.00214	CcSEcCtD
Afatinib—ERBB2—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000791	0.0854	CbGdCrCtD
Afatinib—Skin disorder—Calcitriol—osteoporosis	0.000788	0.00212	CcSEcCtD
Afatinib—Insomnia—Estropipate—osteoporosis	0.000782	0.0021	CcSEcCtD
Afatinib—Eye disorder—Zoledronate—osteoporosis	0.00078	0.0021	CcSEcCtD
Afatinib—Dysgeusia—Pamidronate—osteoporosis	0.000779	0.0021	CcSEcCtD
Afatinib—Back pain—Pamidronate—osteoporosis	0.000769	0.00207	CcSEcCtD
Afatinib—Muscle spasms—Pamidronate—osteoporosis	0.000765	0.00206	CcSEcCtD
Afatinib—Dyspepsia—Estropipate—osteoporosis	0.000761	0.00205	CcSEcCtD
Afatinib—Insomnia—Raloxifene—osteoporosis	0.000757	0.00204	CcSEcCtD
Afatinib—Mediastinal disorder—Zoledronate—osteoporosis	0.000752	0.00203	CcSEcCtD
Afatinib—Eye disorder—Conjugated Estrogens—osteoporosis	0.000751	0.00202	CcSEcCtD
Afatinib—Insomnia—Ibandronate—osteoporosis	0.00075	0.00202	CcSEcCtD
Afatinib—Dyspepsia—Alendronate—osteoporosis	0.000749	0.00202	CcSEcCtD
Afatinib—Cough—Ethinyl Estradiol—osteoporosis	0.000749	0.00202	CcSEcCtD
Afatinib—Upper respiratory tract infection—Estradiol—osteoporosis	0.000747	0.00201	CcSEcCtD
Afatinib—Gastrointestinal disorder—Estropipate—osteoporosis	0.000746	0.00201	CcSEcCtD
Afatinib—Fatigue—Estropipate—osteoporosis	0.000745	0.00201	CcSEcCtD
Afatinib—Constipation—Estropipate—osteoporosis	0.000739	0.00199	CcSEcCtD
Afatinib—Alopecia—Zoledronate—osteoporosis	0.000738	0.00199	CcSEcCtD
Afatinib—Dyspepsia—Raloxifene—osteoporosis	0.000737	0.00198	CcSEcCtD
Afatinib—Insomnia—Calcitriol—osteoporosis	0.000734	0.00198	CcSEcCtD
Afatinib—Mental disorder—Zoledronate—osteoporosis	0.000731	0.00197	CcSEcCtD
Afatinib—Cough—Risedronate—osteoporosis	0.00073	0.00197	CcSEcCtD
Afatinib—Dyspepsia—Ibandronate—osteoporosis	0.000729	0.00196	CcSEcCtD
Afatinib—Constipation—Alendronate—osteoporosis	0.000728	0.00196	CcSEcCtD
Afatinib—Weight decreased—Estradiol—osteoporosis	0.000727	0.00196	CcSEcCtD
Afatinib—Malnutrition—Zoledronate—osteoporosis	0.000727	0.00196	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000726	0.00195	CcSEcCtD
Afatinib—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000724	0.00195	CcSEcCtD
Afatinib—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000723	0.00195	CcSEcCtD
Afatinib—Pneumonia—Estradiol—osteoporosis	0.000721	0.00194	CcSEcCtD
Afatinib—Decreased appetite—Ibandronate—osteoporosis	0.00072	0.00194	CcSEcCtD
Afatinib—Infestation NOS—Estradiol—osteoporosis	0.000717	0.00193	CcSEcCtD
Afatinib—Infestation—Estradiol—osteoporosis	0.000717	0.00193	CcSEcCtD
Afatinib—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000715	0.00193	CcSEcCtD
Afatinib—Fatigue—Ibandronate—osteoporosis	0.000714	0.00192	CcSEcCtD
Afatinib—Dysgeusia—Zoledronate—osteoporosis	0.000712	0.00192	CcSEcCtD
Afatinib—Alopecia—Conjugated Estrogens—osteoporosis	0.00071	0.00191	CcSEcCtD
Afatinib—Constipation—Ibandronate—osteoporosis	0.000709	0.00191	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000708	0.0019	CcSEcCtD
Afatinib—Pruritus—Etidronic acid—osteoporosis	0.000707	0.0019	CcSEcCtD
Afatinib—Decreased appetite—Calcitriol—osteoporosis	0.000705	0.0019	CcSEcCtD
Afatinib—Mental disorder—Conjugated Estrogens—osteoporosis	0.000704	0.0019	CcSEcCtD
Afatinib—Back pain—Zoledronate—osteoporosis	0.000703	0.00189	CcSEcCtD
Afatinib—Malnutrition—Conjugated Estrogens—osteoporosis	0.0007	0.00188	CcSEcCtD
Afatinib—Muscle spasms—Zoledronate—osteoporosis	0.000699	0.00188	CcSEcCtD
Afatinib—Urinary tract infection—Estradiol—osteoporosis	0.000697	0.00188	CcSEcCtD
Afatinib—Conjunctivitis—Estradiol—osteoporosis	0.000697	0.00188	CcSEcCtD
Afatinib—Infection—Ethinyl Estradiol—osteoporosis	0.000696	0.00187	CcSEcCtD
Afatinib—Cough—Pamidronate—osteoporosis	0.000694	0.00187	CcSEcCtD
Afatinib—Constipation—Calcitriol—osteoporosis	0.000694	0.00187	CcSEcCtD
Afatinib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000687	0.00185	CcSEcCtD
Afatinib—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000685	0.00184	CcSEcCtD
Afatinib—Diarrhoea—Etidronic acid—osteoporosis	0.000683	0.00184	CcSEcCtD
Afatinib—Body temperature increased—Estropipate—osteoporosis	0.000683	0.00184	CcSEcCtD
Afatinib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00068	0.00183	CcSEcCtD
Afatinib—Infection—Risedronate—osteoporosis	0.000679	0.00183	CcSEcCtD
Afatinib—Hepatobiliary disease—Estradiol—osteoporosis	0.000678	0.00182	CcSEcCtD
Afatinib—Back pain—Conjugated Estrogens—osteoporosis	0.000677	0.00182	CcSEcCtD
Afatinib—Epistaxis—Estradiol—osteoporosis	0.000676	0.00182	CcSEcCtD
Afatinib—Body temperature increased—Alendronate—osteoporosis	0.000673	0.00181	CcSEcCtD
Afatinib—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000673	0.00181	CcSEcCtD
Afatinib—Nervous system disorder—Risedronate—osteoporosis	0.00067	0.0018	CcSEcCtD
Afatinib—Skin disorder—Risedronate—osteoporosis	0.000663	0.00179	CcSEcCtD
Afatinib—Body temperature increased—Raloxifene—osteoporosis	0.000662	0.00178	CcSEcCtD
Afatinib—Body temperature increased—Ibandronate—osteoporosis	0.000655	0.00176	CcSEcCtD
Afatinib—Infection—Pamidronate—osteoporosis	0.000645	0.00174	CcSEcCtD
Afatinib—Body temperature increased—Calcitriol—osteoporosis	0.000641	0.00173	CcSEcCtD
Afatinib—Nervous system disorder—Pamidronate—osteoporosis	0.000637	0.00171	CcSEcCtD
Afatinib—Urinary tract disorder—Estradiol—osteoporosis	0.000635	0.00171	CcSEcCtD
Afatinib—Vomiting—Etidronic acid—osteoporosis	0.000635	0.00171	CcSEcCtD
Afatinib—Cough—Zoledronate—osteoporosis	0.000634	0.00171	CcSEcCtD
Afatinib—Connective tissue disorder—Estradiol—osteoporosis	0.000632	0.0017	CcSEcCtD
Afatinib—Urethral disorder—Estradiol—osteoporosis	0.000631	0.0017	CcSEcCtD
Afatinib—Rash—Etidronic acid—osteoporosis	0.00063	0.0017	CcSEcCtD
Afatinib—Dermatitis—Etidronic acid—osteoporosis	0.000629	0.00169	CcSEcCtD
Afatinib—Headache—Etidronic acid—osteoporosis	0.000626	0.00168	CcSEcCtD
Afatinib—Asthenia—Estropipate—osteoporosis	0.00062	0.00167	CcSEcCtD
Afatinib—Insomnia—Risedronate—osteoporosis	0.000618	0.00166	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000614	0.00165	CcSEcCtD
Afatinib—Pruritus—Estropipate—osteoporosis	0.000611	0.00165	CcSEcCtD
Afatinib—Asthenia—Alendronate—osteoporosis	0.000611	0.00164	CcSEcCtD
Afatinib—Cough—Conjugated Estrogens—osteoporosis	0.000611	0.00164	CcSEcCtD
Afatinib—Dyspnoea—Risedronate—osteoporosis	0.000609	0.00164	CcSEcCtD
Afatinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000605	0.00163	CcSEcCtD
Afatinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000604	0.00163	CcSEcCtD
Afatinib—Pruritus—Alendronate—osteoporosis	0.000602	0.00162	CcSEcCtD
Afatinib—Dyspepsia—Risedronate—osteoporosis	0.000601	0.00162	CcSEcCtD
Afatinib—Eye disorder—Estradiol—osteoporosis	0.000601	0.00162	CcSEcCtD
Afatinib—Constipation—Ethinyl Estradiol—osteoporosis	0.000599	0.00161	CcSEcCtD
Afatinib—Asthenia—Ibandronate—osteoporosis	0.000595	0.0016	CcSEcCtD
Afatinib—Nausea—Etidronic acid—osteoporosis	0.000593	0.0016	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000592	0.00159	CcSEcCtD
Afatinib—Diarrhoea—Estropipate—osteoporosis	0.000591	0.00159	CcSEcCtD
Afatinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.00059	0.00159	CcSEcCtD
Afatinib—Infection—Zoledronate—osteoporosis	0.000589	0.00159	CcSEcCtD
Afatinib—Fatigue—Risedronate—osteoporosis	0.000589	0.00159	CcSEcCtD
Afatinib—Insomnia—Pamidronate—osteoporosis	0.000587	0.00158	CcSEcCtD
Afatinib—Pruritus—Ibandronate—osteoporosis	0.000586	0.00158	CcSEcCtD
Afatinib—Constipation—Risedronate—osteoporosis	0.000584	0.00157	CcSEcCtD
Afatinib—Diarrhoea—Alendronate—osteoporosis	0.000582	0.00157	CcSEcCtD
Afatinib—Asthenia—Calcitriol—osteoporosis	0.000582	0.00157	CcSEcCtD
Afatinib—Nervous system disorder—Zoledronate—osteoporosis	0.000582	0.00157	CcSEcCtD
Afatinib—Mediastinal disorder—Estradiol—osteoporosis	0.00058	0.00156	CcSEcCtD
Afatinib—Dyspnoea—Pamidronate—osteoporosis	0.000579	0.00156	CcSEcCtD
Afatinib—Skin disorder—Zoledronate—osteoporosis	0.000576	0.00155	CcSEcCtD
Afatinib—Pruritus—Calcitriol—osteoporosis	0.000574	0.00155	CcSEcCtD
Afatinib—Diarrhoea—Raloxifene—osteoporosis	0.000573	0.00154	CcSEcCtD
Afatinib—Dyspepsia—Pamidronate—osteoporosis	0.000571	0.00154	CcSEcCtD
Afatinib—Dizziness—Estropipate—osteoporosis	0.000571	0.00154	CcSEcCtD
Afatinib—Alopecia—Estradiol—osteoporosis	0.000568	0.00153	CcSEcCtD
Afatinib—Infection—Conjugated Estrogens—osteoporosis	0.000567	0.00153	CcSEcCtD
Afatinib—Diarrhoea—Ibandronate—osteoporosis	0.000567	0.00153	CcSEcCtD
Afatinib—Decreased appetite—Pamidronate—osteoporosis	0.000564	0.00152	CcSEcCtD
Afatinib—Mental disorder—Estradiol—osteoporosis	0.000564	0.00152	CcSEcCtD
Afatinib—Dizziness—Alendronate—osteoporosis	0.000563	0.00152	CcSEcCtD
Afatinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000561	0.00151	CcSEcCtD
Afatinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00056	0.00151	CcSEcCtD
Afatinib—Malnutrition—Estradiol—osteoporosis	0.00056	0.00151	CcSEcCtD
Afatinib—Fatigue—Pamidronate—osteoporosis	0.00056	0.00151	CcSEcCtD
Afatinib—Constipation—Pamidronate—osteoporosis	0.000555	0.00149	CcSEcCtD
Afatinib—Diarrhoea—Calcitriol—osteoporosis	0.000555	0.00149	CcSEcCtD
Afatinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000555	0.00149	CcSEcCtD
Afatinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000554	0.00149	CcSEcCtD
Afatinib—Dizziness—Raloxifene—osteoporosis	0.000554	0.00149	CcSEcCtD
Afatinib—Vomiting—Estropipate—osteoporosis	0.000549	0.00148	CcSEcCtD
Afatinib—Dysgeusia—Estradiol—osteoporosis	0.000548	0.00148	CcSEcCtD
Afatinib—Dizziness—Ibandronate—osteoporosis	0.000548	0.00148	CcSEcCtD
Afatinib—Rash—Estropipate—osteoporosis	0.000545	0.00147	CcSEcCtD
Afatinib—Dermatitis—Estropipate—osteoporosis	0.000544	0.00147	CcSEcCtD
Afatinib—Back pain—Estradiol—osteoporosis	0.000542	0.00146	CcSEcCtD
Afatinib—Headache—Estropipate—osteoporosis	0.000541	0.00146	CcSEcCtD
Afatinib—Vomiting—Alendronate—osteoporosis	0.000541	0.00146	CcSEcCtD
Afatinib—Body temperature increased—Risedronate—osteoporosis	0.00054	0.00145	CcSEcCtD
Afatinib—Muscle spasms—Estradiol—osteoporosis	0.000538	0.00145	CcSEcCtD
Afatinib—Rash—Alendronate—osteoporosis	0.000537	0.00144	CcSEcCtD
Afatinib—Insomnia—Zoledronate—osteoporosis	0.000536	0.00144	CcSEcCtD
Afatinib—Dermatitis—Alendronate—osteoporosis	0.000536	0.00144	CcSEcCtD
Afatinib—Headache—Alendronate—osteoporosis	0.000533	0.00144	CcSEcCtD
Afatinib—Vomiting—Raloxifene—osteoporosis	0.000532	0.00143	CcSEcCtD
Afatinib—Dyspnoea—Zoledronate—osteoporosis	0.000529	0.00142	CcSEcCtD
Afatinib—Rash—Raloxifene—osteoporosis	0.000528	0.00142	CcSEcCtD
Afatinib—Dermatitis—Raloxifene—osteoporosis	0.000527	0.00142	CcSEcCtD
Afatinib—Vomiting—Ibandronate—osteoporosis	0.000527	0.00142	CcSEcCtD
Afatinib—Headache—Raloxifene—osteoporosis	0.000524	0.00141	CcSEcCtD
Afatinib—Rash—Ibandronate—osteoporosis	0.000523	0.00141	CcSEcCtD
Afatinib—Dermatitis—Ibandronate—osteoporosis	0.000522	0.00141	CcSEcCtD
Afatinib—Dyspepsia—Zoledronate—osteoporosis	0.000522	0.00141	CcSEcCtD
Afatinib—Headache—Ibandronate—osteoporosis	0.000519	0.0014	CcSEcCtD
Afatinib—Insomnia—Conjugated Estrogens—osteoporosis	0.000516	0.00139	CcSEcCtD
Afatinib—Vomiting—Calcitriol—osteoporosis	0.000516	0.00139	CcSEcCtD
Afatinib—Decreased appetite—Zoledronate—osteoporosis	0.000516	0.00139	CcSEcCtD
Afatinib—Nausea—Estropipate—osteoporosis	0.000513	0.00138	CcSEcCtD
Afatinib—Body temperature increased—Pamidronate—osteoporosis	0.000513	0.00138	CcSEcCtD
Afatinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000512	0.00138	CcSEcCtD
Afatinib—Rash—Calcitriol—osteoporosis	0.000512	0.00138	CcSEcCtD
Afatinib—Fatigue—Zoledronate—osteoporosis	0.000511	0.00138	CcSEcCtD
Afatinib—Dermatitis—Calcitriol—osteoporosis	0.000511	0.00138	CcSEcCtD
Afatinib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000509	0.00137	CcSEcCtD
Afatinib—Headache—Calcitriol—osteoporosis	0.000508	0.00137	CcSEcCtD
Afatinib—Constipation—Zoledronate—osteoporosis	0.000507	0.00137	CcSEcCtD
Afatinib—Nausea—Alendronate—osteoporosis	0.000506	0.00136	CcSEcCtD
Afatinib—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000503	0.00135	CcSEcCtD
Afatinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000503	0.00135	CcSEcCtD
Afatinib—Nausea—Raloxifene—osteoporosis	0.000497	0.00134	CcSEcCtD
Afatinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000496	0.00134	CcSEcCtD
Afatinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000496	0.00133	CcSEcCtD
Afatinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000493	0.00133	CcSEcCtD
Afatinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000492	0.00133	CcSEcCtD
Afatinib—Nausea—Ibandronate—osteoporosis	0.000492	0.00133	CcSEcCtD
Afatinib—Asthenia—Risedronate—osteoporosis	0.00049	0.00132	CcSEcCtD
Afatinib—Cough—Estradiol—osteoporosis	0.000489	0.00132	CcSEcCtD
Afatinib—Constipation—Conjugated Estrogens—osteoporosis	0.000488	0.00131	CcSEcCtD
Afatinib—Pruritus—Risedronate—osteoporosis	0.000483	0.0013	CcSEcCtD
Afatinib—Nausea—Calcitriol—osteoporosis	0.000482	0.0013	CcSEcCtD
Afatinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000479	0.00129	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000473	0.00127	CcSEcCtD
Afatinib—Body temperature increased—Zoledronate—osteoporosis	0.000469	0.00126	CcSEcCtD
Afatinib—Diarrhoea—Risedronate—osteoporosis	0.000467	0.00126	CcSEcCtD
Afatinib—Asthenia—Pamidronate—osteoporosis	0.000466	0.00125	CcSEcCtD
Afatinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000463	0.00125	CcSEcCtD
Afatinib—Pruritus—Pamidronate—osteoporosis	0.000459	0.00124	CcSEcCtD
Afatinib—Infection—Estradiol—osteoporosis	0.000454	0.00122	CcSEcCtD
Afatinib—Dizziness—Risedronate—osteoporosis	0.000452	0.00122	CcSEcCtD
Afatinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000451	0.00122	CcSEcCtD
Afatinib—Nervous system disorder—Estradiol—osteoporosis	0.000448	0.00121	CcSEcCtD
Afatinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000445	0.0012	CcSEcCtD
Afatinib—Diarrhoea—Pamidronate—osteoporosis	0.000444	0.0012	CcSEcCtD
Afatinib—Skin disorder—Estradiol—osteoporosis	0.000444	0.0012	CcSEcCtD
Afatinib—Rash—Ethinyl Estradiol—osteoporosis	0.000442	0.00119	CcSEcCtD
Afatinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000441	0.00119	CcSEcCtD
Afatinib—Headache—Ethinyl Estradiol—osteoporosis	0.000439	0.00118	CcSEcCtD
Afatinib—Vomiting—Risedronate—osteoporosis	0.000434	0.00117	CcSEcCtD
Afatinib—Rash—Risedronate—osteoporosis	0.000431	0.00116	CcSEcCtD
Afatinib—Dermatitis—Risedronate—osteoporosis	0.00043	0.00116	CcSEcCtD
Afatinib—Dizziness—Pamidronate—osteoporosis	0.000429	0.00116	CcSEcCtD
Afatinib—Headache—Risedronate—osteoporosis	0.000428	0.00115	CcSEcCtD
Afatinib—Asthenia—Zoledronate—osteoporosis	0.000425	0.00115	CcSEcCtD
Afatinib—Pruritus—Zoledronate—osteoporosis	0.00042	0.00113	CcSEcCtD
Afatinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000416	0.00112	CcSEcCtD
Afatinib—Insomnia—Estradiol—osteoporosis	0.000413	0.00111	CcSEcCtD
Afatinib—Vomiting—Pamidronate—osteoporosis	0.000413	0.00111	CcSEcCtD
Afatinib—Asthenia—Conjugated Estrogens—osteoporosis	0.00041	0.0011	CcSEcCtD
Afatinib—Rash—Pamidronate—osteoporosis	0.000409	0.0011	CcSEcCtD
Afatinib—Dermatitis—Pamidronate—osteoporosis	0.000409	0.0011	CcSEcCtD
Afatinib—Dyspnoea—Estradiol—osteoporosis	0.000407	0.0011	CcSEcCtD
Afatinib—Headache—Pamidronate—osteoporosis	0.000407	0.0011	CcSEcCtD
Afatinib—Diarrhoea—Zoledronate—osteoporosis	0.000406	0.00109	CcSEcCtD
Afatinib—Nausea—Risedronate—osteoporosis	0.000406	0.00109	CcSEcCtD
Afatinib—Pruritus—Conjugated Estrogens—osteoporosis	0.000404	0.00109	CcSEcCtD
Afatinib—Dyspepsia—Estradiol—osteoporosis	0.000402	0.00108	CcSEcCtD
Afatinib—Decreased appetite—Estradiol—osteoporosis	0.000397	0.00107	CcSEcCtD
Afatinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000395	0.00106	CcSEcCtD
Afatinib—Fatigue—Estradiol—osteoporosis	0.000394	0.00106	CcSEcCtD
Afatinib—Dizziness—Zoledronate—osteoporosis	0.000392	0.00106	CcSEcCtD
Afatinib—Constipation—Estradiol—osteoporosis	0.000391	0.00105	CcSEcCtD
Afatinib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000391	0.00105	CcSEcCtD
Afatinib—Nausea—Pamidronate—osteoporosis	0.000386	0.00104	CcSEcCtD
Afatinib—Dizziness—Conjugated Estrogens—osteoporosis	0.000378	0.00102	CcSEcCtD
Afatinib—Vomiting—Zoledronate—osteoporosis	0.000377	0.00102	CcSEcCtD
Afatinib—Rash—Zoledronate—osteoporosis	0.000374	0.00101	CcSEcCtD
Afatinib—Dermatitis—Zoledronate—osteoporosis	0.000374	0.00101	CcSEcCtD
Afatinib—Headache—Zoledronate—osteoporosis	0.000372	0.001	CcSEcCtD
Afatinib—Vomiting—Conjugated Estrogens—osteoporosis	0.000363	0.000977	CcSEcCtD
Afatinib—Body temperature increased—Estradiol—osteoporosis	0.000361	0.000973	CcSEcCtD
Afatinib—Rash—Conjugated Estrogens—osteoporosis	0.00036	0.000969	CcSEcCtD
Afatinib—Dermatitis—Conjugated Estrogens—osteoporosis	0.00036	0.000968	CcSEcCtD
Afatinib—Headache—Conjugated Estrogens—osteoporosis	0.000358	0.000963	CcSEcCtD
Afatinib—Nausea—Zoledronate—osteoporosis	0.000352	0.000948	CcSEcCtD
Afatinib—Nausea—Conjugated Estrogens—osteoporosis	0.000339	0.000913	CcSEcCtD
Afatinib—Asthenia—Estradiol—osteoporosis	0.000328	0.000883	CcSEcCtD
Afatinib—Pruritus—Estradiol—osteoporosis	0.000323	0.000871	CcSEcCtD
Afatinib—Diarrhoea—Estradiol—osteoporosis	0.000313	0.000842	CcSEcCtD
Afatinib—Dizziness—Estradiol—osteoporosis	0.000302	0.000814	CcSEcCtD
Afatinib—Vomiting—Estradiol—osteoporosis	0.000291	0.000782	CcSEcCtD
Afatinib—Rash—Estradiol—osteoporosis	0.000288	0.000776	CcSEcCtD
Afatinib—Dermatitis—Estradiol—osteoporosis	0.000288	0.000775	CcSEcCtD
Afatinib—Headache—Estradiol—osteoporosis	0.000286	0.000771	CcSEcCtD
Afatinib—Nausea—Estradiol—osteoporosis	0.000271	0.000731	CcSEcCtD
Afatinib—EGFR—Adaptive Immune System—IRS2—osteoporosis	4.77e-05	0.000138	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6R—osteoporosis	4.77e-05	0.000138	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—IL6—osteoporosis	4.76e-05	0.000138	CbGpPWpGaD
Afatinib—ERBB4—Disease—IRS1—osteoporosis	4.76e-05	0.000138	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TLN1—osteoporosis	4.74e-05	0.000137	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—P4HB—osteoporosis	4.73e-05	0.000137	CbGpPWpGaD
Afatinib—EGFR—Disease—ENO1—osteoporosis	4.68e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—IL6—osteoporosis	4.68e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—IL6—osteoporosis	4.68e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	4.68e-05	0.000135	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6R—osteoporosis	4.66e-05	0.000135	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GAPDH—osteoporosis	4.65e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—IL6—osteoporosis	4.63e-05	0.000134	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6R—osteoporosis	4.62e-05	0.000134	CbGpPWpGaD
Afatinib—EGFR—Disease—PSMA2—osteoporosis	4.61e-05	0.000133	CbGpPWpGaD
Afatinib—EGFR—Disease—PSMA5—osteoporosis	4.61e-05	0.000133	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—IRS2—osteoporosis	4.6e-05	0.000133	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—IL6—osteoporosis	4.59e-05	0.000133	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—IL6—osteoporosis	4.57e-05	0.000132	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ATIC—osteoporosis	4.54e-05	0.000132	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PNP—osteoporosis	4.54e-05	0.000132	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6R—osteoporosis	4.54e-05	0.000131	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—RAP1A—osteoporosis	4.53e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—Disease—ENO1—osteoporosis	4.51e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	4.51e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—IL6—osteoporosis	4.51e-05	0.00013	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—IL6—osteoporosis	4.51e-05	0.00013	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CALCA—osteoporosis	4.5e-05	0.00013	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6R—osteoporosis	4.47e-05	0.000129	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—IL6—osteoporosis	4.47e-05	0.000129	CbGpPWpGaD
Afatinib—LCK—Disease—PSMA5—osteoporosis	4.44e-05	0.000129	CbGpPWpGaD
Afatinib—LCK—Disease—PSMA2—osteoporosis	4.44e-05	0.000129	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ADCY5—osteoporosis	4.43e-05	0.000128	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—IL6—osteoporosis	4.43e-05	0.000128	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—IL6—osteoporosis	4.41e-05	0.000128	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ADCY5—osteoporosis	4.36e-05	0.000126	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IRS1—osteoporosis	4.34e-05	0.000126	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IRS2—osteoporosis	4.33e-05	0.000125	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IGF1—osteoporosis	4.3e-05	0.000125	CbGpPWpGaD
Afatinib—EGFR—Disease—CALCA—osteoporosis	4.3e-05	0.000124	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SPP1—osteoporosis	4.28e-05	0.000124	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—IL6—osteoporosis	4.25e-05	0.000123	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—P4HB—osteoporosis	4.24e-05	0.000123	CbGpPWpGaD
Afatinib—EGFR—Immune System—KL—osteoporosis	4.23e-05	0.000122	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SPP1—osteoporosis	4.22e-05	0.000122	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IRS1—osteoporosis	4.18e-05	0.000121	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—IRS1—osteoporosis	4.17e-05	0.000121	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	4.14e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Disease—CALCA—osteoporosis	4.14e-05	0.00012	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTH—osteoporosis	4.12e-05	0.000119	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KL—osteoporosis	4.09e-05	0.000118	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—P4HB—osteoporosis	4.09e-05	0.000118	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6R—osteoporosis	4.08e-05	0.000118	CbGpPWpGaD
Afatinib—PHKG2—Disease—IL6—osteoporosis	4.08e-05	0.000118	CbGpPWpGaD
Afatinib—LCK—Immune System—KL—osteoporosis	4.07e-05	0.000118	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RAP1A—osteoporosis	4.05e-05	0.000117	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CNR2—osteoporosis	4.02e-05	0.000116	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—IRS1—osteoporosis	4.02e-05	0.000116	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	4e-05	0.000116	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	3.99e-05	0.000116	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTH—osteoporosis	3.97e-05	0.000115	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFATC1—osteoporosis	3.95e-05	0.000114	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6R—osteoporosis	3.93e-05	0.000114	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—DKK1—osteoporosis	3.92e-05	0.000114	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RAP1A—osteoporosis	3.91e-05	0.000113	CbGpPWpGaD
Afatinib—EGFR—Disease—KL—osteoporosis	3.9e-05	0.000113	CbGpPWpGaD
Afatinib—ABL1—Immune System—AGER—osteoporosis	3.89e-05	0.000113	CbGpPWpGaD
Afatinib—ABL1—Immune System—ADCY5—osteoporosis	3.87e-05	0.000112	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IRS2—osteoporosis	3.87e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CNR2—osteoporosis	3.87e-05	0.000112	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—OXCT1—osteoporosis	3.86e-05	0.000112	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CA2—osteoporosis	3.86e-05	0.000112	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IRS2—osteoporosis	3.82e-05	0.00011	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFATC1—osteoporosis	3.81e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—LEP—osteoporosis	3.79e-05	0.00011	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IRS1—osteoporosis	3.78e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—DKK1—osteoporosis	3.78e-05	0.000109	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—WNT1—osteoporosis	3.78e-05	0.000109	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MGLL—osteoporosis	3.76e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—Disease—KL—osteoporosis	3.76e-05	0.000109	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—IL6—osteoporosis	3.76e-05	0.000109	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1B—osteoporosis	3.74e-05	0.000108	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—LEP—osteoporosis	3.73e-05	0.000108	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—IL6—osteoporosis	3.7e-05	0.000107	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1B—osteoporosis	3.68e-05	0.000107	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGA—osteoporosis	3.68e-05	0.000106	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ENO1—osteoporosis	3.66e-05	0.000106	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—WNT1—osteoporosis	3.64e-05	0.000105	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—ADCY5—osteoporosis	3.62e-05	0.000105	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ESR1—osteoporosis	3.62e-05	0.000105	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PSMA2—osteoporosis	3.6e-05	0.000104	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PSMA5—osteoporosis	3.6e-05	0.000104	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ESR1—osteoporosis	3.56e-05	0.000103	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6R—osteoporosis	3.55e-05	0.000103	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGA—osteoporosis	3.54e-05	0.000103	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1B—osteoporosis	3.54e-05	0.000103	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTHLH—osteoporosis	3.42e-05	9.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BMP2—osteoporosis	3.42e-05	9.89e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IRS2—osteoporosis	3.39e-05	9.81e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IRS1—osteoporosis	3.38e-05	9.79e-05	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—IL6—osteoporosis	3.37e-05	9.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGB—osteoporosis	3.34e-05	9.68e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IRS1—osteoporosis	3.33e-05	9.64e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AGER—osteoporosis	3.32e-05	9.62e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ADCY5—osteoporosis	3.31e-05	9.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTHLH—osteoporosis	3.29e-05	9.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BMP2—osteoporosis	3.29e-05	9.53e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—POMC—osteoporosis	3.26e-05	9.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PSMA5—osteoporosis	3.23e-05	9.35e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PSMA2—osteoporosis	3.23e-05	9.35e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGB—osteoporosis	3.22e-05	9.33e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—POMC—osteoporosis	3.21e-05	9.28e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—IDH2—osteoporosis	3.2e-05	9.27e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AGER—osteoporosis	3.2e-05	9.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ADCY5—osteoporosis	3.2e-05	9.27e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TGFB1—osteoporosis	3.19e-05	9.25e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ADCY5—osteoporosis	3.19e-05	9.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—IL6—osteoporosis	3.18e-05	9.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6R—osteoporosis	3.18e-05	9.19e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TGFB1—osteoporosis	3.13e-05	9.07e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IGF1—osteoporosis	3.13e-05	9.07e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6R—osteoporosis	3.13e-05	9.06e-05	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL6—osteoporosis	3.12e-05	9.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PSMA5—osteoporosis	3.11e-05	9.01e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PSMA2—osteoporosis	3.11e-05	9.01e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SPP1—osteoporosis	3.1e-05	8.96e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IGF1—osteoporosis	3.09e-05	8.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—IL6—osteoporosis	3.07e-05	8.88e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ADCY5—osteoporosis	3.06e-05	8.85e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP27A1—osteoporosis	3.01e-05	8.71e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CALCA—osteoporosis	3.01e-05	8.71e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—osteoporosis	2.98e-05	8.63e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IRS1—osteoporosis	2.96e-05	8.57e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.95e-05	8.55e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.95e-05	8.53e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ADCY5—osteoporosis	2.95e-05	8.53e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ACP5—osteoporosis	2.93e-05	8.48e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP19A1—osteoporosis	2.92e-05	8.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CALCA—osteoporosis	2.9e-05	8.39e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IRS2—osteoporosis	2.9e-05	8.38e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—osteoporosis	2.88e-05	8.34e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTHFR—osteoporosis	2.81e-05	8.14e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IRS2—osteoporosis	2.8e-05	8.11e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IRS2—osteoporosis	2.79e-05	8.08e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6R—osteoporosis	2.78e-05	8.05e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.76e-05	7.98e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.75e-05	7.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—LEP—osteoporosis	2.74e-05	7.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KL—osteoporosis	2.73e-05	7.91e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TGFB1—osteoporosis	2.73e-05	7.9e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TPI1—osteoporosis	2.72e-05	7.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—osteoporosis	2.72e-05	7.86e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTHFR—osteoporosis	2.71e-05	7.84e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—osteoporosis	2.7e-05	7.82e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—osteoporosis	2.69e-05	7.78e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—TGFB1—osteoporosis	2.68e-05	7.76e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IRS2—osteoporosis	2.67e-05	7.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—POMC—osteoporosis	2.66e-05	7.71e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—osteoporosis	2.65e-05	7.66e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—TGFB1—osteoporosis	2.64e-05	7.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KL—osteoporosis	2.63e-05	7.62e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ESR1—osteoporosis	2.62e-05	7.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6R—osteoporosis	2.6e-05	7.52e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TGFB1—osteoporosis	2.58e-05	7.47e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IRS2—osteoporosis	2.58e-05	7.46e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—P4HB—osteoporosis	2.56e-05	7.41e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—osteoporosis	2.55e-05	7.38e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IRS1—osteoporosis	2.53e-05	7.32e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GAPDH—osteoporosis	2.51e-05	7.27e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—RAP1A—osteoporosis	2.45e-05	7.08e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IRS1—osteoporosis	2.44e-05	7.08e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IRS1—osteoporosis	2.44e-05	7.05e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—osteoporosis	2.41e-05	6.97e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ADCY5—osteoporosis	2.39e-05	6.92e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GPX1—osteoporosis	2.38e-05	6.89e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6R—osteoporosis	2.38e-05	6.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—POMC—osteoporosis	2.35e-05	6.81e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IRS1—osteoporosis	2.33e-05	6.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6R—osteoporosis	2.3e-05	6.65e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6R—osteoporosis	2.29e-05	6.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF1—osteoporosis	2.26e-05	6.56e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IRS1—osteoporosis	2.25e-05	6.51e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—osteoporosis	2.2e-05	6.36e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6R—osteoporosis	2.19e-05	6.35e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—osteoporosis	2.19e-05	6.34e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—osteoporosis	2.16e-05	6.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADCY5—osteoporosis	2.14e-05	6.2e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—osteoporosis	2.13e-05	6.15e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—osteoporosis	2.11e-05	6.12e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6R—osteoporosis	2.11e-05	6.12e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—osteoporosis	2.07e-05	6e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SPP1—osteoporosis	2.07e-05	5.99e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADCY5—osteoporosis	2.06e-05	5.97e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—osteoporosis	2.06e-05	5.95e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—osteoporosis	2.02e-05	5.85e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SPP1—osteoporosis	2e-05	5.78e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—osteoporosis	1.99e-05	5.76e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO1—osteoporosis	1.98e-05	5.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PSMA5—osteoporosis	1.95e-05	5.64e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PSMA2—osteoporosis	1.95e-05	5.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—osteoporosis	1.88e-05	5.45e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—osteoporosis	1.88e-05	5.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS2—osteoporosis	1.87e-05	5.42e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—osteoporosis	1.85e-05	5.37e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—osteoporosis	1.85e-05	5.35e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LEP—osteoporosis	1.83e-05	5.3e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—osteoporosis	1.82e-05	5.26e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—osteoporosis	1.81e-05	5.23e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS2—osteoporosis	1.8e-05	5.22e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—osteoporosis	1.77e-05	5.11e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—POMC—osteoporosis	1.76e-05	5.09e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—osteoporosis	1.75e-05	5.07e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—osteoporosis	1.75e-05	5.06e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—osteoporosis	1.74e-05	5.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—osteoporosis	1.69e-05	4.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS1—osteoporosis	1.63e-05	4.73e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—osteoporosis	1.58e-05	4.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP19A1—osteoporosis	1.58e-05	4.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS1—osteoporosis	1.58e-05	4.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—POMC—osteoporosis	1.57e-05	4.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6R—osteoporosis	1.54e-05	4.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—POMC—osteoporosis	1.52e-05	4.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—osteoporosis	1.51e-05	4.38e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6R—osteoporosis	1.48e-05	4.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—osteoporosis	1.46e-05	4.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—osteoporosis	1.41e-05	4.1e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—osteoporosis	1.39e-05	4.03e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—osteoporosis	1.36e-05	3.94e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—osteoporosis	1.36e-05	3.93e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—osteoporosis	1.3e-05	3.76e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—osteoporosis	1.3e-05	3.75e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADCY5—osteoporosis	1.29e-05	3.74e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—osteoporosis	1.29e-05	3.73e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—osteoporosis	1.25e-05	3.63e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—osteoporosis	1.25e-05	3.62e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—osteoporosis	1.24e-05	3.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—osteoporosis	1.19e-05	3.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—osteoporosis	1.16e-05	3.35e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—osteoporosis	1.06e-05	3.06e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—osteoporosis	1.02e-05	2.96e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—osteoporosis	1.02e-05	2.95e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—osteoporosis	9.77e-06	2.83e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—POMC—osteoporosis	9.5e-06	2.75e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—osteoporosis	9.41e-06	2.73e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—osteoporosis	9.1e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—osteoporosis	9.08e-06	2.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—osteoporosis	8.77e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—osteoporosis	8.75e-06	2.53e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—osteoporosis	6.84e-06	1.98e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—osteoporosis	6.59e-06	1.91e-05	CbGpPWpGaD
